Adjuvant radiotherapy for thymoma after surgery
Official title: An Open-label, Multi-center, Randomized Phase III Study of Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection
Run by Fudan University · NCT02633553 · Data updated 2026-11-12
This study is testing if adding radiation therapy after surgery can help people with stage II or III thymoma live longer and have better outcomes.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 238 (estimated) |
| Sponsor | Fudan University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Status | Recruiting |
| Started | January 10, 2018 |
| Main results expected | December 2029 |
| Study ends | December 2029 |
| Registry record updated | April 24, 2026 |
| Trial ID | NCT02633553 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 to 75 with pathologically confirmed stage II or III thymoma who have undergone complete surgical resection.
✕Probably not a fit
Patients with distant metastases, those who have received prior radiotherapy or chemotherapy, or those with active infections may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the effectiveness of adjuvant radiotherapy in improving survival rates for patients with stage II or III thymoma following complete surgical resection. It aims to clarify the controversial benefits of radiotherapy in this patient population, as previous studies have shown that complete resection generally leads to better outcomes. The trial will enroll patients aged 18 to 75 who have undergone complete resection within the last three months and meet specific health criteria. Participants will receive adjuvant radiotherapy to assess its impact on their survival.
Why it matters
Potential benefit: If successful, this study could provide evidence that adjuvant radiotherapy significantly improves survival rates for patients with stage II or III thymoma after surgery.
How similar studies have gone: While there have been studies on thymoma treatment, the specific approach of adjuvant radiotherapy after complete resection for stage II or III thymoma remains somewhat controversial and is not widely tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 18\~75 years old; Eastern Cooperative Oncology Group performance status of 0 to 2; Pathologically confirmed masaoka stage II or III thymoma; Have adequate bone marrow, hepatic, and renal function; Patients receive complete resection within 3 months; Written informed consent. Exclusion Criteria: Patients with distant metastases; Patients underwent radiotherapy or chemotherapy; Patients who have malignancy history excluding carcinoma in situ of cervix in the previous five years; Active clinical pulmonary infection; Pregnant or nursing.
Where it's running
-
Kailiang Wu
Shanghai, Shanghai Municipality, China Recruiting
Study contacts
- Study coordinator: Kailiang Wu, MD.PhD.
- Email: wukailiang@aliyun.com
- Phone: +86 64175590
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Tislelizumab plus anlotinib as a second-line treatment for thymoma and thymic carcinoma
This trial will test whether combining tislelizumab with anlotinib is safe and can control thymoma or thymic carcinoma in people whose cancer progressed after first-line chemotherapy (with or without immunotherapy).
-
Combining glucocorticoids with chemoradiotherapy for thymoma treatment
This study is testing if adding a steroid called methylprednisolone to standard chemotherapy and radiation can help people with advanced or recurring thymoma have better treatment results.
-
Using hypofractionated radiotherapy for thymic epithelial tumors
This study is testing if a shorter, more intense type of radiation therapy can help people with thymic epithelial tumors after surgery feel better and have fewer side effects compared to the standard treatment.
-
Using AI to improve diagnosis and recurrence prediction in thymic tumors
This study is testing if artificial intelligence can help doctors better diagnose thymic tumors and predict the chances of them coming back for patients with these rare cancers.
-
Testing a new treatment for advanced thymic tumors
This study is testing a new drug to see if it can help adults with advanced thymic tumors who haven't had success with other treatments.
-
Comparing robot-assisted and video-assisted surgery for thymoma treatment
This study is testing whether robot-assisted surgery or video-assisted surgery is better for treating patients with thymoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.